logo-loader

Summit Therapeutics to begin Phase 3 studies of ridinilazol this quarter

Published: 10:12 11 Feb 2019 EST

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) CEO Glyn Edwards caught up with Proactive Investors at the BIO CEO & Investor Conference in New York.

Edwards says the company expects to begin treating its first patient this quarter in its Phase 3 study of ridinilazol.

Summit is currently developing new mechanism antibiotics for infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens and is using its proprietary Discuva Platform to expand its pipeline.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

1 hour, 8 minutes ago